Investigating the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus
Investigating the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus
This trial is conducted in Europe. The aim of this trial is to investigate the effectiveness
 of Tresiba® (insulin degludec) after switching basal insulin in a population with type 1 or
 type 2 diabetes mellitus.

 EU-TREAT (EUropean TREsiba AudiT)
Inclusion Criteria:

 -  Informed consent will be obtained before any study-related activities. Study-related
 activities are any data collection from the medical records of the patient

 -  Age at least 18 years at the time of Tresiba® initiation

 -  T1DM or insulin-treated T2DM patients

 -  Switched to Tresiba® (with or without prandial insulin) after any basal insulin (with
 or without prandial insulin). Switch must have occurred at least 6 months prior to
 data collection and the patient may or may not be treated with Tresiba® at the time of
 patient selection

 -  Previously treated with any basal insulin (with or without prandial insulin) for at
 least 6 months prior to switching to Tresiba®

 -  At least one documented medical visit in the first 9 months after Tresiba® initiation

 -  Minimum available data at the time of Tresiba® initiation: age, type of diabetes,
 HbA1c (Glycated haemoglobin), duration of diabetes, duration and type of insulin
 treatment, medical follow-up at the study site of at least 1 year, and an eGFR
 (Estimated glomerular filtration rate )value in the last 12 months

 Exclusion Criteria:

 -  Previous participation in this study. Participation is defined as having signed the
 Informed Consent

 -  Participation in a diabetes clinical trial or receipt of any investigational medicinal
 product up to 12 months before or any time after the initiation of Tresiba®

 -  Current participation in another non-interventional study on insulin degludec
 (Tresiba®)

 -  Patients treated by continuous subcutaneous insulin infusion or premix insulin in the
 6 months prior to receiving Tresiba®